Both the first vaccine produced to combat COVID-19, and the country of its production would not only have the financial edge over other countries, but also geopolitical supremacy. The current statistics of COVID-19 reported around hundreds of thousands of deaths in the world and counting. This article deals with the vaccine development process and costs related to COVID-19 and also highlights the significance of open alliances in the biotech sector in a post-COVID regime. This article focuses on ways in which the challenging worldwide health crises of the current pandemic can be overcome in distinctly local ways through open, transparent, and collaborative practices.